Drug Trial Radar · NCT01681524
Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI
Last checked: Nov 20, 2026Latest source record: May 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Nov 2012
Primary completion
Feb 2014
Study completion May 2014
Sponsor
- Lead sponsor
- Lantheus Medical ImagingIndustry
- Sponsor type
- Industry
- First posted
- Sep 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the use of Flurpiridaz F18 injection in patients with CAD to determine if the study drug in PET imaging is better than SPECT imaging currently used for this purpose.
Conditions
- Coronary Artery Disease
Interventions
Flurpiridaz F18Drug
Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blinded Image assessment for PET & SPECT perfusion and for interventional coronary angiographyTime frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.